JP2016523260A - そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 - Google Patents

そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 Download PDF

Info

Publication number
JP2016523260A
JP2016523260A JP2016521898A JP2016521898A JP2016523260A JP 2016523260 A JP2016523260 A JP 2016523260A JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016523260 A JP2016523260 A JP 2016523260A
Authority
JP
Japan
Prior art keywords
cellulopitant
cream
administered
therapeutically effective
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016521898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523260A5 (enExample
Inventor
シャオミン チャン
シャオミン チャン
エドワード エフ． シュニパー
エドワード エフ． シュニパー
アンドリュー ジェイ． パールマン
アンドリュー ジェイ． パールマン
ジェイムズ ダブリュ． ラリック
ジェイムズ ダブリュ． ラリック
Original Assignee
タイガーキャット ファーマ インコーポレイテッド
タイガーキャット ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by タイガーキャット ファーマ インコーポレイテッド, タイガーキャット ファーマ インコーポレイテッド filed Critical タイガーキャット ファーマ インコーポレイテッド
Publication of JP2016523260A publication Critical patent/JP2016523260A/ja
Publication of JP2016523260A5 publication Critical patent/JP2016523260A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016521898A 2013-06-24 2014-06-24 そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用 Ceased JP2016523260A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
US13/925,509 2013-06-24
US61/838,784 2013-06-24
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087897A Division JP2019142960A (ja) 2013-06-24 2019-05-07 そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用

Publications (2)

Publication Number Publication Date
JP2016523260A true JP2016523260A (ja) 2016-08-08
JP2016523260A5 JP2016523260A5 (enExample) 2017-08-03

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016521898A Ceased JP2016523260A (ja) 2013-06-24 2014-06-24 そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用
JP2019087897A Pending JP2019142960A (ja) 2013-06-24 2019-05-07 そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019087897A Pending JP2019142960A (ja) 2013-06-24 2019-05-07 そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用

Country Status (13)

Country Link
EP (1) EP3013336A1 (enExample)
JP (2) JP2016523260A (enExample)
KR (1) KR20160023692A (enExample)
CN (1) CN105473138A (enExample)
AU (2) AU2014302694B2 (enExample)
BR (1) BR112015031724A2 (enExample)
CA (1) CA2915474A1 (enExample)
HK (1) HK1223820A1 (enExample)
IL (1) IL243189A0 (enExample)
MX (2) MX366728B (enExample)
PH (2) PH12015502777A1 (enExample)
RU (1) RU2666219C2 (enExample)
WO (1) WO2014209962A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533381A (ja) * 2017-09-13 2020-11-19 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． トラジピタントによるアトピー性皮膚炎の改善された治療

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アプレピタントのエマルジョン製剤
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
EP3411013A1 (en) * 2016-02-01 2018-12-12 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
WO2018005695A1 (en) * 2016-06-29 2018-01-04 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
WO2019152232A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519728A (ja) * 2004-01-27 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド ヒドロイソインドリンタキキニン受容体アンタゴニスト

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
US20100036135A1 (en) 2005-07-11 2010-02-11 Merck & Co., Inc. Process for Making Hydroisoindoline Tachykinin Receptor Antagonists
US7893091B2 (en) 2005-10-04 2011-02-22 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
US20100209496A1 (en) 2006-09-06 2010-08-19 Eleni Dokou Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20090270477A1 (en) 2006-11-02 2009-10-29 Kuethe Jeffrey T Polymorphs of a hydroisoindoline tachykinin receptor antagonist
CA2681749A1 (en) 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519728A (ja) * 2004-01-27 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド ヒドロイソインドリンタキキニン受容体アンタゴニスト

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUR. J. PHARMACOL., vol. 491, JPN6018006162, 2004, pages 191 - 194, ISSN: 0004069449 *
J. MED. CHEM., vol. 52, JPN6018006161, 2009, pages 3039 - 3046, ISSN: 0004069448 *
PLOS ONE, vol. Vol.5 Iss.6, JPN6018006163, 2010, pages 10968, ISSN: 0004069450 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533381A (ja) * 2017-09-13 2020-11-19 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． トラジピタントによるアトピー性皮膚炎の改善された治療
JP7347743B2 (ja) 2017-09-13 2023-09-20 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療

Also Published As

Publication number Publication date
BR112015031724A2 (pt) 2017-07-25
PH12020500255A1 (en) 2021-02-22
CA2915474A1 (en) 2014-12-31
RU2666219C2 (ru) 2018-09-06
HK1223820A1 (zh) 2017-08-11
KR20160023692A (ko) 2016-03-03
MX2015017763A (es) 2016-06-21
EP3013336A1 (en) 2016-05-04
AU2014302694B2 (en) 2019-10-17
PH12015502777A1 (en) 2016-03-21
RU2015154037A (ru) 2017-07-28
JP2019142960A (ja) 2019-08-29
CN105473138A (zh) 2016-04-06
AU2020200259A1 (en) 2020-02-06
AU2014302694A1 (en) 2016-01-07
MX366728B (es) 2019-07-22
IL243189A0 (en) 2016-02-29
WO2014209962A1 (en) 2014-12-31
MX2019008643A (es) 2019-09-10

Similar Documents

Publication Publication Date Title
US10702499B2 (en) Use of NK-1 receptor antagonists in pruritus
JP2019142960A (ja) そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用
US11026920B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
JP2019131594A (ja) 新規の使用
US20200121695A1 (en) Compositions and methods for treating itch, skin inflammation, and pruritus
HK40032890A (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170620

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170620

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190507

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190521

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190618

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190625

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190705

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190709

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200324

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200609

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201109

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210119

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210224

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210325

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210727